» Articles » PMID: 26465925

Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo

Overview
Journal PLoS One
Date 2015 Oct 15
PMID 26465925
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-penetrating peptides (CPPs) are a group of peptides, which have the ability to cross cell membrane bilayers. CPPs themselves can exert biological activity and can be formed endogenously. Fragmentary studies demonstrate their ability to enhance transport of different cargoes across the blood-brain barrier (BBB). However, comparative, quantitative data on the BBB permeability of different CPPs are currently lacking. Therefore, the in vivo BBB transport characteristics of five chemically diverse CPPs, i.e. pVEC, SynB3, Tat 47-57, transportan 10 (TP10) and TP10-2, were determined. The results of the multiple time regression (MTR) analysis revealed that CPPs show divergent BBB influx properties: Tat 47-57, SynB3, and especially pVEC showed very high unidirectional influx rates of 4.73 μl/(g × min), 5.63 μl/(g × min) and 6.02 μl/(g × min), respectively, while the transportan analogs showed a negligible to low brain influx. Using capillary depletion, it was found that 80% of the influxed peptides effectively reached the brain parenchyma. Except for pVEC, all peptides showed a significant efflux out of the brain. Co-injection of pVEC with radioiodinated bovine serum albumin (BSA) did not enhance the brain influx of radiodionated BSA, indicating that pVEC does not itself significantly alter the BBB properties. A saturable mechanism could not be demonstrated by co-injecting an excess dose of non-radiolabeled CPP. No significant regional differences in brain influx were observed, with the exception for pVEC, for which the regional variations were only marginal. The observed BBB influx transport properties cannot be correlated with their cell-penetrating ability, and therefore, good CPP properties do not imply efficient brain influx.

Citing Articles

Two-step ultrasonic cavitation controlled delivery of brain exogenous nucleic acids for ischemic stroke using acoustic-cationic-polymeric-nanodroplets.

Dong W, Wang G, Chai Y, Li W, Liu S, Liu H Drug Deliv Transl Res. 2025; .

PMID: 40048146 DOI: 10.1007/s13346-025-01828-6.


Novel Tissue-Specific Multifunctionalized Nanotechnological Platform Encapsulating Riluzole Against Motor Neuron Diseases.

Esteruelas G, Ettcheto M, Haro I, Herrando-Grabulosa M, Gaja-Capdevila N, Gomara M Int J Nanomedicine. 2025; 20:2273-2288.

PMID: 40007904 PMC: 11853070. DOI: 10.2147/IJN.S479819.


Exploring cotton plant compounds for novel treatments against brain-eating Naegleria fowleri: An In-silico approach.

Zaman A, Noor S, Ahmad I, Shehroz M, Alhajri N, Ahmed S PLoS One. 2025; 20(2):e0319032.

PMID: 39992954 PMC: 11849825. DOI: 10.1371/journal.pone.0319032.


Strategies to Enhance Nanocrystal Formulations for Overcoming Physiological Barriers Across Diverse Routes of Administration.

Yanamadala Y, Muthumula C, Khare S, Gokulan K Int J Nanomedicine. 2025; 20():367-402.

PMID: 39816376 PMC: 11733173. DOI: 10.2147/IJN.S494224.


Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases.

Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J Pharmaceutics. 2025; 16(12.

PMID: 39771589 PMC: 11677317. DOI: 10.3390/pharmaceutics16121611.


References
1.
Lindgren M, Hallbrink M, Elmquist A, Langel U . Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J. 2003; 377(Pt 1):69-76. PMC: 1223834. DOI: 10.1042/BJ20030760. View

2.
Copolovici D, Langel K, Eriste E, Langel U . Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014; 8(3):1972-94. DOI: 10.1021/nn4057269. View

3.
Elmquist A, Langel U . In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem. 2003; 384(3):387-93. DOI: 10.1515/BC.2003.044. View

4.
Pardridge W, Eisenberg J, Cefalu W . Absence of albumin receptor on brain capillaries in vivo or in vitro. Am J Physiol. 1985; 249(3 Pt 1):E264-7. DOI: 10.1152/ajpendo.1985.249.3.E264. View

5.
Oess S, Hildt E . Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000; 7(9):750-8. DOI: 10.1038/sj.gt.3301154. View